Today

Schott Pharma, Takeda and Corplex move recycled-PP vial trays into routine use

Schott Pharma has delivered the first full batch of vials packed in trays made with recycled polypropylene to Takeda's manufacturing site in Singen, Germany, taking a closed-loop system developed with tray maker Corplex from pilot phase into routine operation. The trays contain up to 70% recycled polypropylene drawn from a controlled loop, and a peer-reviewed independent life-cycle assessment puts their greenhouse gas emissions up to 50% below equivalent all-virgin trays. Formal change controls and trials at Takeda confirmed the trays are processable in pharmaceutical manufacturing.

Why this mattersA qualified closed-loop recycled-content system for single-use pharma intermediate packaging gives drugmakers and tray suppliers a template ahead of tighter EU rules.

  • The first full batch of vials in recycled-PP trays reached Takeda's Singen site in Germany in August 2026, following a pilot phase
  • The trays contain up to 70% recycled polypropylene sourced from a controlled closed loop
  • A peer-reviewed independent life-cycle assessment by The LCA Centre in October 2024 found up to 50% lower greenhouse gas emissions than equivalent trays made entirely from virgin polypropylene
  • Development ran over two years and included a risk assessment, a ton-scale production study and equivalency testing against virgin-material trays
  • Corplex returns the closed-loop material into new tray production and Schott Pharma uses the trays as intermediate packaging for vial shipments to Takeda
  • The system targets Scope 3, Category 1 emissions across the three companies' value chain
Schott AG Corplex counterparty Takeda Pharmaceutical counterparty
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-09-18 · Edited before publication: Three items are not in the excerpts: the ISO 14040/14044 references, the 2R to 30R vial format list, and the plan to extend to further European customers. The source describes the assessment only as ISO-compliant and peer-reviewed. Headline also named Schott rather than Schott Pharma, the entity in the source.